Negative Affect Circuit Subtypes and Neural, Behavioral, and Affective Responses to MDMA: A Randomized Clinical...

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• 3,4-methylenedioxymethamphetamine (MDMA) shows promise for treating posttraumatic stress disorder (PTSD).
• Identifying individuals who benefit most from MDMA and understanding its neural mechanisms are critical research gaps.
• Stratifying patients by neural circuit profiles could enable personalized MDMA treatment strategies.

Purpose of the Study:

• To determine if baseline negative affect circuit profiles, specifically in response to nonconscious threat stimuli, can differentiate acute responses to MDMA.
• Investigate the potential of neuroimaging biomarkers for predicting MDMA treatment outcomes.

Main Methods:

• A randomized, double-blind, within-participant, placebo-controlled clinical trial was conducted.
• Participants with subthreshold PTSD symptoms and early life trauma underwent functional magnetic resonance imaging (fMRI) to assess the negative affect circuit.
• Stratification was based on baseline amygdala reactivity to nonconscious threat stimuli (NTN task).

Main Results:

• Participants were stratified into high (NTNA+) and low (NTNA-) amygdala reactivity subgroups.
• The NTNA+ subgroup showed significant reductions in amygdala and subgenual anterior cingulate cortex (sgACC) activity after MDMA administration compared to the NTNA- subgroup.
• MDMA also increased sgACC-amygdala connectivity and likability of threat expressions in the NTNA+ group.

Conclusions:

• MDMA acutely normalized negative affect circuit reactivity in individuals with heightened baseline amygdala reactivity.
• Neuroimaging can identify prospective biomarkers for personalized MDMA-based therapies.
• This study highlights the potential for precision medicine in MDMA-assisted therapy for psychiatric disorders.